Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-25-032954
Filing Date
2025-04-17
Accepted
2025-04-17 16:05:24
Documents
2
Period of Report
2025-04-15

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 2239
2 POWER OF ATTORNEY ea023852801ex24-1_protara.htm EX-24.1 5450
  Complete submission text file 0001213900-25-032954.txt   9348
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Issuer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O PROTARA THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, THIRD FLOOR NEW YORK NY 10010
Business Address
Nicacio Leonardo Viana (Reporting) CIK: 0002064901 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36694 | Film No.: 25847279